Effect of proton pump inhibitor and COX2 inbitor upon Barrett's intestinal metaplasia.

我们研究了质子泵抑制剂（PPI）是否可以降低致癌风险。巴雷特食管（BE）本研究通过对BE内镜活检标本进行免疫组化分析，观察其在PPI治疗前后Ki-67、COX-2、CDX-2、sulo - lewisa表达的变化。在PPI治疗6个月后，Ki-76（细胞增殖诱导因子）和COX-2（增殖相关因子）的表达明显降低。CDX-2（肠转录因子）和sulo - lewisa（肠粘蛋白）的表达有降低的趋势。相比之下，组胺2受体拮抗剂（H2RA）治疗后，Ki-67、COX-2、CDX-2、sulfo-Le^a的表达没有显著降低。我们评估了PPI治疗会降低COX-2的表达，从而降低细胞增殖。有报道称COX-2和CDX-2之间的表达可能与p38 MAPK通路有关。因此，我们检测了PPI治疗前后BE中Phospho-p38的表达。在- PPL治疗前后，BE上皮细胞和基质细胞中- phospho -p38的表达均显著降低。因此，我们认为PPI-可以通过p38抑制COX-2和CDX-2的表达。MAPK途径，从而导致细胞增殖和肠化生。会。减少。

We examined whether proton pump inhibitor(PPI) may diminish the risk of carcinogenesis. in Barrett's esophagus (BE). In our study, endoscopic biopsy specimens of BE was analyzed for change in the expression of Ki-67, COX-2, CDX-2, sulfo-Lewisa by immunohistochemistry before and after treatment with PPI.6 months after treatment with PPI, there was a significant decrease in the expression of Ki-76 (cell proliferation maker) and COX-2 (proliferation-related agent). And there was a tendency to decrease in the expression of CDX-2(intestinal transcription factor) and sulfo-Lewisa (intestinal mucin).In contrast, treatment with histamin2 receptor antagonist (H2RA) showed no significant decrease in the expression of Ki-67, COX-2, CDX-2, sulfo-Le^a.We evaluated that treatment with PPI would reduce the expression of COX-2 and consequently cell proliferation would decrease.It was reported that the expression of between COX-2 and CDX-2 would be associated with p38 MAPK pathway. Accordingly, we examined the expression of Phospho-p38 in BE before and after treatment with PPI.There was a significant decrease in the expression of -Phospho-p38 in both epithelial cells and stromal cells in BE before and-after treatment with- PPL.Therefore, we concluded- that PPI- would inhibit- the- expression of both COX-2 and CDX-2 via p38. MAPK pathway and that consequently cell proliferation and intestinal metaplasia. would. diminish.